Abstracts tagged "Lupus nephritis"

Abstract Number: 1648 • 2014 ACR/ARHP Annual Meeting
Urinary T Cells and Macrophages Strongly Reflect the Disease Activity, Kidney Function, and the Histopathologic Classification in Patients with Lupus Nephritis
Yoko Wada¹, Minoru Sakatsume², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ³School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Lupus nephritis (LN) is one of the common manifestations of systemic lupus erythematosus (SLE), and the occurrence of LN is considered to be a…
Abstract Number: 1635 • 2014 ACR/ARHP Annual Meeting
Association Between Carrying at Least One Apolipoprotein1 Variant Allele and Hypertension in Lupus Patients with Normal Renal Function
Ashira Blazer¹, H. Michael Belmont², Robert Clancy³, Peter M. Izmirly⁴ and Jill P. Buyon⁵, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Rheumatology, NYU Medical Center, New York, NY, ⁴Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose The apolipoprotein1 (APOL1) gene encodes a 3 domain protein found both in serum and intracellularly in endothelial cells among other cell types. Variant APOL1…
Abstract Number: 1611 • 2014 ACR/ARHP Annual Meeting
Modular Transcriptional Neutrophil Signature As Predictive of Nephritis and of Its Severity in SLE Patients
Noémie Jourde-Chiche Sr.¹, Stéphane Burtey², Nathalie Bardin³, Elizabeth Whalen⁴, Bertrand Gondouin⁵, Scott Presnell⁶, Bertrand Dussol⁷, Gilles Kaplanski⁸, Jean-Robert Harle⁹, Yvon Berland², Virginia Pascual¹⁰, Damien Chaussabel⁴ and Laurent Chiche¹¹, ¹Nephrology, Aix-Marseille Université - APHM, Marseille, France, ²Nephrology, APHM, Marseille, France, ³Hopital de la Conception, Marseille, France, ⁴BRI, seattle, WA, ⁵Department of Nephrology, APHM, Marseille, France, ⁶bri, seattle, WA, ⁷AP Marseille, Marseille, France, ⁸INSERM U608, Marseille, France, ⁹Internal Medicine, APHM, Marseille, France, ¹⁰Baylor University, Dallas, TX, ¹¹147 Boulevard Baille, CHU Marseille, Marseille, France
Background/Purpose: Lupus nephritis (LN) is a serious complication of SLE. Reliable biomarkers to assess and/or predict renal involvement in SLE patients are needed. The aim…
Abstract Number: 1307 • 2014 ACR/ARHP Annual Meeting
Monitoring of Mid-Interval Plasma Levels of Mycophenolic Acid in Pediatric Lupus Nephritis Patients
Joyce S Hui-Yuen¹, Kristi Truong², Liza Mariel Bermudez-Santiago¹, Amy J. Starr³, Andrew Eichenfield⁴, Lisa F. Imundo⁵ and Anca Askanase³, ¹Morgan Stanley Children's Hospital of New York Presbyterian, Columbia University Medical Center, New York, NY, ²Doctor of Pharmacy degree program, St John's University, Queens, NY, ³Columbia University Medical Center, New York, NY, ⁴Div of Pediatric Rheumatology, Children's Hosp of New York, New York, NY, ⁵Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY
Background/Purpose: Mycophenolate mofetil (MMF) is often used to treat lupus nephritis (LN) and extra-renal lupus in children with SLE. Plasma levels of mycophenolic acid (MPA)…
Abstract Number: 1303 • 2014 ACR/ARHP Annual Meeting
Accuracy of Laboratory Measures and Clinical Renal Activity Indices for Reflecting Biopsy-Proven Lupus Nephritis (LN) Activity
Khalid Abulaban¹, Stacy P. Ardoin², Marisa Klein-Gitelman³, Kelly A. Rouster-Stevens⁴, Michael Bennett⁵, Lori B. Tucker⁶, Kasha Wiley⁷, Shannen Nelson⁸, Karen Onel⁹, Nora G. Singer¹⁰, B Anne Eberhard¹¹, Kathleen M. O'Neil¹², Elizabeth B. Brooks¹³, Lawrence K. Jung¹⁴, Lisa F. Imundo¹⁵, Tracey Wright¹⁶, David Witte¹⁷, Jun Ying¹⁸, Prasad Devarajan⁵ and Hermine I. Brunner¹⁹, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ³Anne & Robert H Lurie Childrens Hospital of Chicago, Chicago, IL, ⁴Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁵Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Rheumatology, Cincinnati Children's Hospital Medical Center, c, OH, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁰Medicine, Division of Rhuematology, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, ¹¹Pediatrics/Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ¹²Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹³Pediatric Infectious Disease, Rheumatology and Geographic Medicine, Case Medical Center, Cleveland, OH, ¹⁴Pediatric Rheumatology, Children's National Medical Center, Washington, DC, ¹⁵Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, ¹⁶Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹⁷Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ¹⁸University of Cincinnati, Cincinnati, OH, ¹⁹Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose : LN is common in childhood-onset Systemic Lupus Erythematosus (cSLE). Kidney biopsies are impractical to assess the course of LN given their invasiveness and…
Abstract Number: 1295 • 2014 ACR/ARHP Annual Meeting
Childhood-Onset Systemic Lupus Erythematosus: Short-Term Treatment Response Rates in Proliferative Lupus Nephritis
Andrea Human¹, Simon Yu Tian², Earl D. Silverman³ and Deborah M. Levy¹, ¹Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ²Rheumatology and Program of Child Health Evaluative Sciences, The Hospital for Sick Children, Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Proliferative Lupus Nephritis (PLN) occurs in up to 50% of patients with childhood-onset systemic lupus erythematosus (cSLE). PLN is a significant source of morbidity and…
Abstract Number: 961 • 2014 ACR/ARHP Annual Meeting
Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study
John G. Hanly for the Systemic Lupus International Collaborating Clinics¹, Aidan O'Keeffe², Li Su³, Murray B. Urowitz⁴, Juanita Romero-Diaz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Sasha R Bernatsky⁸, Ann E. Clarke⁹, Daniel J. Wallace¹⁰, Joan T. Merrill¹¹, David A. Isenberg¹², Anisur Rahman¹³, Ellen M. Ginzler¹⁴, Paul Fortin¹⁵, Dafna D. Gladman⁴, Jorge Sanchez-Guerrero¹⁶, Michelle Petri¹⁷, Ian Bruce¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Cynthia Aranow²¹, Graciela S. Alarcon²², Barri Fessler²³, Kristjan Steinsson²⁴, Ola Nived²⁵, Gunnar Sturfelt²⁵, Susan Manzi²⁶, Munther A. Khamashta²⁷, Ronald F. van Vollenhoven²⁸, Asad Zoma²⁹, Manuel Ramos-Casals³⁰, Guillermo Ruiz-Irastorza³¹, S. Sam Lim³², Thomas Stoll³³, Murat Inanc³⁴, Kenneth C. Kalunian³⁵, Diane L. Kamen³⁶, Peter Maddison³⁷, Christine A. Peschken³⁸, Søren Jacobsen³⁹, Anca Askanase⁴⁰, Jill P. Buyon⁴¹, Chris Theriault⁴², Kara Thompson⁴² and Vernon Farewell³, ¹Division of Rheumatology, Dalhousie University and Capital Health, Nova Scotia, Canada, Halifax, NS, Canada, ²MRC Biostatistics Unit, Institute of Public Heath, Cambridge, United Kingdom, ³MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutricion, Mexico city, Mexico, ⁶Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁸Division of Rheumatology and Clinical Epidemiology, McGill University, Montreal, Quebec, QC, Canada, ⁹Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ¹⁰Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹¹Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹³Centre for Rheumatology Research, University College London, London, United Kingdom, ¹⁴Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ¹⁵Medicine, Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, Canada, ¹⁶Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ¹⁹Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ²⁰Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, IL, ²¹Feinstein Institute for Medical Research, Mahasset, NY, ²²Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²³Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁴Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland, ²⁵Department of Rheumatology, University Hospital Lund, Lund, Sweden, ²⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²⁷Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ²⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²⁹Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁰Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ³¹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ³²Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ³³Kantonsspital Geissbergstr, Schaffhausen, Switzerland, ³⁴Division of Rheumatology, Department of Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, ³⁵UCSD School of Medicine, La Jolla, CA, ³⁶Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ³⁷Ysbyty Gwynedd Bangor, North Wales, United Kingdom, ³⁸Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³⁹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴⁰Columbia University Medical Center, New York, NY, ⁴¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴²Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Improved immunosuppressive therapies have changed the treatment of lupus nephritis (LN) over the past decade. We examined the outcome of LN with current standard…
Abstract Number: 2990 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus Patients: A Single Center Study
Javier Merayo-Chalico¹, Elia Apodaca², Ana Barrera-Vargas³, Jorge Alcocer-Varela³ and Diana Gómez-Martín³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is a well-known but rare complication in systemic lupus erythematosus (SLE) patients (
Abstract Number: 972 • 2014 ACR/ARHP Annual Meeting
Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010
Eric Y Yen¹, Magda Shaheen², Jennifer MP Woo³, Deborah K. McCurdy⁴ and Ram Raj Singh⁵, ¹Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ²Charles R. Drew University of Medicine and Science, Los Angeles, CA, ³UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁴Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁵Medicine, UCLA Division of Rheumatology, Los Angeles, CA
Title: Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010Background/Purpose: Many epidemiologic studies of systemic…
Abstract Number: 2738 • 2014 ACR/ARHP Annual Meeting
Shk-186, a Kv1.3 channel inhibitor That Targets Effector Memory T Cells: Safety and Tolerability in Humans and Its Evaluation in a Model of Rapidly Progressive Glomerulonephritis
Ernesto J. Muñoz-Elías¹, Kayla Norton¹, John B. Grigg¹, Liz Bromley¹, David W. Peckham¹, Eric J. Tarcha¹, Jared Odegard², James Qin², Megan Yuasa³, Anne Stevens⁴, Wayel H. Abdulahad⁵, Galina Schmunk⁶, K. George Chandy⁶ and Shawn P. Iadonato¹, ¹Kineta Inc., Seattle, WA, ²Benaroya Research Institute at Virginia Mason, Seattle, WA, ³Seattle Children's Res Institute, Seattle Children's Research Institute, Seattle, WA, ⁴Seattle Children's Res Inst, Seattle Children's Hospital, Seattle, WA, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Physiology, Biophysics, and Surgery, UC Irvine, Irvine, CA
Background/Purpose: The voltage-gated potassium channel Kv1.3 is a novel target for the treatment of autoimmune disorders including psoriatic and rheumatic diseases. ShK-186 is an exquisitely specific,…
Abstract Number: 962 • 2014 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis of the Risk of Serious Infections with Immunosuppressives for Lupus Nephritis
Jasvinder A. Singh¹, Alomgir Hossain², Ahmed Kotb² and George Wells³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Ottawa, Ottawa, ON, Canada, ³Cardiovascular Resarch Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose To compare the risk of serious infections of immunosuppressive medications used for the treatment of lupus nephritis. Methods We performed an up to date…
Abstract Number: 1826 • 2014 ACR/ARHP Annual Meeting
A Renal Activity Index May Predict Histological Activity in Lupus Nephritis in Children
Khalid Abulaban¹, Michael Bennett², Marisa Klein-Gitelman³, Stacy P. Ardoin⁴, Kelly A. Rouster-Stevens⁵, Lori B. Tucker⁶, Kasha Wiley⁷, Shannen Nelson⁸, Karen Onel⁹, Nora G. Singer¹⁰, Kathleen M. O'Neil¹¹, Elizabeth Brooks¹², B Anne Eberhard¹³, Lawrence K. Jung¹⁴, Lisa F. Imundo¹⁵, Tracey Wright¹⁶, David Witte¹⁷, Jun Ying¹⁸, Prasad Devarajan² and Hermine I. Brunner¹⁹, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Anne & Robert H Lurie Childrens Hospital of Chicago, Chicago, IL, ⁴Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ⁵Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Rheumatology, Cincinnati Children's Hospital Medical Center, c, OH, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁰Medicine, Division of Rhuematology, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, ¹¹Division of Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹²Rheumatology, Univ Hospitals of Cleveland, Cleveland, OH, ¹³Pediatrics/Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ¹⁴Pediatric Rheumatology, Children's National Medical Center, Washington, DC, ¹⁵Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, ¹⁶Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹⁷Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ¹⁸University of Cincinnati, Cincinnati, OH, ¹⁹Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose Lupus Nephritis (LN) occurs in up to 80% of childhood-onset Systemic Lupus Erythematosus (cSLE) and it has a worse prognosis than adults. The current…
Abstract Number: 963 • 2014 ACR/ARHP Annual Meeting
Reduction in Proteinuria and Normalization of C4 Complement Levels Predict Response to Treatment of Lupus Nephritis with Low-Dose Pulse Cyclophosphamide and Abatacept
Sarah Goglin¹, David Wofsy², Miriam G. Cisternas³ and Maria Dall'era¹, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³MGC Data Services, Carlsbad, CA
Background/Purpose: The response to treatment of lupus nephritis is unpredictable. There is a need to identify clinical and biochemical characteristics that can predict treatment outcome…
Abstract Number: 1672 • 2014 ACR/ARHP Annual Meeting
Facilitating the Medication Decision-Making process—What Do Patients with Lupus Nephritis Say?
Ricahrd Shewchuk¹, Haiyan Qu², W. Winn Chatham², Jinoos Yazdany³, Maria Dall'era⁴ and Jasvinder A. Singh⁵, ¹University fo Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵University of Alabama and VA Medical Center, Birmingham, AL
Background/Purpose: Low medication adherence in lupus nephritis puts patients at risk for poor outcomes, but to our knowledge, relatively little is known about what patients…
Abstract Number: 1667 • 2014 ACR/ARHP Annual Meeting
Probability of 3 and 6 Month Complete Response in Lupus Nephritis
Homa Timlin¹, Michelle Petri¹ and Laurence S Magder², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

Background/Purpose: Lupus nephritis is a major cause of morbidity and mortality. The complete response rate is the most sensitive in detecting differences among therapeutic regimens.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].